Jagsonpal Pharmaceuticals reported a 22.16% year-on-year increase in standalone net profit to ₹131.89 million for the quarter ended June 30, 2026, driven by an 8.75% rise in revenue from operations to ₹822.32 million. EBITDA for the quarter grew to ₹173 million from ₹142 million in the same period last year, with EBITDA margin expanding to 21.05% from 18.78%, reflecting stronger operational efficiency. The company also announced the acquisition of an 85% equity stake in Aequitas Healthcare Private Limited for ₹208 million, signaling expansion through strategic consolidation. These results were approved by the Board of Directors on July 29, 2026, pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The financial performance reflects improved operational leverage, with total expenses growing at a slower pace than revenue. Net profit for the previous corresponding quarter stood at ₹107.95 million, while revenue was ₹756.12 million. The statutory auditors, Walker Chandiok & Co LLP, issued a limited review report confirming that the unaudited financial results comply with Ind AS 34 and other generally accepted accounting principles in India.

Financial Highlights

The table below presents a summary of key financial metrics for the quarter, reflecting broad-based improvement across revenue, profitability, and per-share earnings.

Revenue from operations increased by ₹66.20 million compared to the same period last year. Other income remained relatively stable at ₹28.33 million, slightly up from ₹28.25 million in Q1FY25. Total income rose to ₹850.65 million from ₹784.37 million.

Expense Analysis

Total expenses for the quarter were ₹673.85 million, up 5.28% year-on-year. Employee benefits expense, a significant cost component, increased to ₹227.78 million from ₹194.41 million in Q1FY25, though this comparison is influenced by exceptional items in the prior year. In the previous fiscal year ended March 31, 2026, the company recorded an exceptional item of ₹20.79 million related to changes in labor laws under the New Labour Codes. No such exceptional items were recorded in Q1FY26.

Cost of materials consumed rose to ₹48.66 million from ₹53.32 million, while purchases of stock-in-trade increased to ₹260.50 million from ₹226.89 million. Finance costs remained negligible at ₹2.51 million. Depreciation and amortization expenses decreased slightly to ₹21.42 million from ₹23.53 million.

Strategic Developments

During the quarter, Jagsonpal Pharmaceuticals entered into a Share Purchase Agreement on June 29, 2026, to acquire an 85% stake in Aequitas Healthcare Private Limited for ₹208 million. The transaction is funded through internal accruals, with existing promoters retaining a 15% shareholding. While the agreement was executed in Q1FY26, the transfer of shares and closing formalities were completed in July 2026, meaning the acquisition did not impact the current quarter's financial results.

Additionally, the company undertook a buy-back of up to 1,600,000 equity shares at ₹250 per share, with an aggregate consideration not exceeding ₹400 million, via the tender offer route. Under the Employee Stock Option Plan 2022, the company granted 153,000 stock options and allotted 473,220 equity shares upon exercise of vested options.

What the Numbers Show

The divergence between revenue growth (8.75%) and expense growth (5.28%) indicates improved operating leverage for Jagsonpal Pharmaceuticals in Q1FY26. EBITDA margin expansion to 21.05% from 18.78% further underscores the strengthening of core operational profitability during the quarter. This efficiency gain directly contributed to the 22.51% surge in profit before tax. The absence of the ₹20.79 million exceptional labor cost burden present in the prior year further enhanced comparability. The acquisition of Aequitas Healthcare positions the company for future scale, although integration benefits will materialize in subsequent quarters.

Jagsonpal Pharmaceuticals has scheduled a conference call with analysts and investors to discuss its financial results for the first quarter of FY27. The meeting is set to take place on July 30, 2026, at 2:30 PM IST, as part of the company's investor engagement activities.

The discussion will be led by the company's senior management, including Managing Director Manish Gupta, Chief Operating Officer Amrut Medhekar, and Chief Financial Officer Nirav Vora. The event is being hosted by Go India Advisors.

Conference Call Details

Participants are required to pre-register to avoid wait time and join using the Diamond Pass facility. The company has advised attendees to dial in at least 5 to 10 minutes prior to the scheduled start time to ensure timely connection.

For further information regarding the conference call, investors may contact Soumya Chhajed or Sheetal Khanduja via email at soumya@goindiaadvisors.com and sheetal@goindiaadvisors.com , respectively.